Citi raised the firm’s price target on Alnylam (ALNY) to $404 from $364 and keeps a Buy rating on the shares. The firm updated commercial stage biotechnology targets into the Q2 reports.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam Pharma’s Promising Growth and Market Potential Justify Buy Rating
- Alnylam price target raised to $384 from $328 at Jefferies
- Alnylam announces reimbursement of OXLUMO in Canada
- Strong Sales Momentum and Growth Potential Drive Buy Rating for Alnylam Pharma’s Amvuttra
- Alnylam’s NeuroFeeL Study: A New Frontier in Amyloidosis Biomarker Research